CNS-directed AAV gene therapy shows milder immune responses compared to systemic administration, reducing peripheral immune activation and systemic toxicities. Direct CNS delivery can bypass ...
Trastuzumab Plus Gemcitabine-Cisplatin for Treatment-Naïve Human Epidermal Growth Factor Receptor 2–Positive Biliary Tract Adenocarcinoma: A Multicenter, Open-Label, Phase II Study (TAB) Patients were ...
Central nervous system (CNS) relapse occurs in roughly one in 20 patients with diffuse large B-cell lymphoma (DLBCL), but in some disease subtypes that risk increases substantially. "In certain ...
Comparative survival after neoadjuvant vs adjuvant systemic therapy in resectable stage II and stage III non-small cell lung cancer: A retrospective study using the National Cancer Database. CNS = ...
SAN FRANCISCO, April 09, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat ...
Central nervous system (CNS) toxicity accounts for 25% of safety failures across drug discovery and development, yet it is rarely detected during standard GLP toxicology studies 1. Seizure risk ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results